Sultan, Hussein
Wu, Juan
Kumai, Takumi
Salazar, Andres M.
Celis, Esteban http://orcid.org/0000-0001-8299-4480
Funding for this research was provided by:
National Cancer Institute (R01CA157303)
Augusta University
Georgia Research Alliance
Article History
Received: 18 December 2017
Accepted: 20 April 2018
First Online: 25 April 2018
Compliance with ethical standards
:
: A. Salazar is President and CEO of Oncovir, Inc. and is developing poly-ICLC (Hiltonol ™) for the clinic. Esteban Celis has filed patent applications based on the use of synthetic peptides and poly-IC combinatorial vaccines. The rights of the patent applications have been transferred to the Moffitt Cancer Center (Tampa, FL). Other authors declare no conflict of interest.
: All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in the experiments involving animals were in accordance with the ethical standards of the Augusta University Institutional Animal Care and Use Committee where all the studies were conducted (Protocol No. 2013 − 0598, approved on 11/21/2016).
: This article does not contain any studies with humans done by any of the authors.